chrisvoncsefalvay/vaers-outcomes huggingface dataset:
got COVID; got COVID; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non-HCP), Program ID: The reporter is the patient.  A patient (no qualifiers provided) received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), in Nov2022 as dose number unknown (booster), single (Batch/Lot number: unknown) for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose number unknown, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "got COVID". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (2022) Positive, notes: I now tested positive.  Clinical course: It was reported that, 6 weeks ago patient received the bivalent COVID booster vaccine and now tested positive. Patient thought he/she was supposed to have protection longer than 6 weeks and wear mask everywhere and continue to follow all recommendations. Patient also thought symptoms were supposed to be "mild" if vaccinated and still got COVID. Patient further stated that his/her symptoms were not mild and will not be recommending vaccine to anyone. Patient's Primary Immunization series completed but unknown manufacturer.  The information on the batch/lot number for BNT162b2, BNT162b2 omi ba.4-5 has been requested and will be submitted if and when received.
01/19 Incredible pain for about 30-45 min. and felt like a heart attack. After a ride in ambulance pain went from a 10 to about a 5 and was wheeled in and immediately rushed in to the EKG, Ultrasound, blood test, and urine test. It was after the blood work and urine sample that they thought it might be gall stones and confirmed this with an Ultrasound. When discovered, was given pain medication and as a prescription and advised to see a G.I. Specialist. I have an appointment with a new G.I. Specialist on 1/28.
Information has been received from a physician concerning a 66 year old female with diabetes, hypertension, lipids high and drug allergy to CIPRO, WELLBUTRIN and Codeine who in November 2004 was vaccinated with the first 0.5mL dose of PNEUMOVAX 23 and on 28-OCT-2008 was vaccinated with the second 0.5mL dose of PNEUMOVAX 23 (lot # 660717/0224X). Concomitant therapy included insulin, "HUMLIN INSULIN 70/30"), GLUCOPHAGE, lovastatin (manufacturer unknown), lisinopril (manufacturer unknown), aspirin, calcium (unspecified) (+) vitamin D (unspecified) and NASACORT AQ. On 28-OCT-2008, within 2 hours after vaccination, the patient experienced redness and swelling at the injection site. The physician expressed a concern that injection was given higher than the deltoid region, closer to the shoulder and might have been injected in the tendon area. The patient was experiencing difficulty moving the right arm. The patient was recovering at the time of this report. The patient visited the office for medical attention. Additional information has been requested.
About 3hrs after administration (1800) pt presenting with bright red rash covering bilateral arms, hands, face, ears, neck, stomach, legs. Reporting pruritus on rash sites, inside mouth, inside ears, inside nose. Rash red in color, raised, splotchy, and warm to touch.  Patient took OTC diphenhydramine 50mg at approximately 1815. As of 1930 pt reporting no relief in symptoms. No reduction in rash sites observed. Pt at this time has not sought professional medical treatment.
Patient complained of lip swelling and numbness in the upper lip. She had already left the observation area at 11:08am and came back at 11:30am with these symptoms. Patient left at 11:40 am by her own will and stated she had decreased numbness and swelling.
PATIENT PRESENTED TO ER WITH COMPLAINT OF DIARRHEA SIN AM OF 4/14/21. ER WORKUP WAS UNREMARKABLE EXCEPT PT WAS HYPOXIC. HOSPATILIST CONSULTED AND PATIENT WAS ADMITTED FOR OBSERVATION DUE TO HYPOXIA
Feeling sick; weak, no strength at all around bedtime; Felt like she was starting to run a temperature; Big red knot; arm started feeling sore; This spontaneous case was reported by a consumer and describes the occurrence of MALAISE (Feeling sick), ASTHENIA (weak, no strength at all around bedtime), PAIN IN EXTREMITY (arm started feeling sore), VACCINATION SITE MASS (Big red knot) and PYREXIA (Felt like she was starting to run a temperature) in a 60-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 013A21A) for COVID-19 vaccination.     Concurrent medical conditions included Breast cancer. Concomitant products included LETROZOLE, ASPIRIN [ACETYLSALICYLIC ACID] and LOSARTAN for an unknown indication.    On 02-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 02-Mar-2021, the patient experienced PAIN IN EXTREMITY (arm started feeling sore). On 03-Mar-2021, the patient experienced VACCINATION SITE MASS (Big red knot). On 09-Mar-2021, the patient experienced MALAISE (Feeling sick), ASTHENIA (weak, no strength at all around bedtime) and PYREXIA (Felt like she was starting to run a temperature). The patient was treated with IBUPROFEN at an unspecified dose and frequency. At the time of the report, MALAISE (Feeling sick), ASTHENIA (weak, no strength at all around bedtime), PAIN IN EXTREMITY (arm started feeling sore), VACCINATION SITE MASS (Big red knot) and PYREXIA (Felt like she was starting to run a temperature) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Treatment information was included Ibuprofen.
Pt vaccinated with DTP developed pallor & extreme lethargy difficult to arouse. Taken to Southern Maryland Hospital, & recovered by the end of the visit.
Swelling and erythema around injection site left thigh 10cm x 16cm. No fever. Erythema and indurations gone by 06/13/04. Exam site for Follow up 6/15/04. No erythema, no swelling.
shingles; This initial spontaneous report was received from a lawyer regarding a case in litigation and refers to patient of unknown age and gender. No information was provided regarding concomitant medications, concurrent conditions or medical history.   In 2014, the patient was vaccinated with a dose of the zoster vaccine live (ZOSTAVAX) (lot number, expiration date, anatomical location and administration route were not reported) at a medicine institute, for the long-term prevention of shingles and/or zoster-related conditions. On an unspecified date, subsequent to the patient's zoster vaccine live (ZOSTAVAX inoculation, patient was treated by a physician for shingles. As a direct and proximate result of the zoster vaccine live (ZOSTAVAX), the patient had and would continue suffer ongoing injuries, including but not limited to: mental and physical pain and suffering; extensive medical care and treatment for these injuries; significant medical and related expenses as a result of these injuries, including but not limited to medical losses and costs including care for hospitalization (on an unknown date), physician care, monitoring, treatment, medications, and supplies. By the time of the report, the patient did not recover from shingles. The event was considered to be related to zoster vaccine live (ZOSTAVAX).
Passed out 3 times on same night (syncope) and sustained injury to head andvlip
On 10/10/2022 had ear infection; Prescribed AUGMENTIN; Had to go back to 10/13/2022 because the medication wasn't working; Was sent to a local hospital; Had an MRI done and diagnosed with Mastoiditis, and had surgery on 10/14/2022 to remove the Mastoiditis; during surgery they put tubes in ears to prevent future ear infections; During surgery discovered a Cerebral Spinal Fluid leak, doctor took some muscle from behind ear to plug the leak; also confirmed Epidural Abscess above the brain and Cerebral Venous Thrombosis of the Sigmoid Sinus; Was hospitalized and was put on an IV of ROCEPHIN; Was given LOVENOX by injection twice a day; Given FLAGYL three times a day; Also received ear drops twice a day; Stayed in hospital until 10/18/2022; Before leaving hospital he was given his Flu shot and had a PICC line placed in his arm to help give him the IV of antibiotics at home; Started regiment of getting ROCEPHIN twice a day; LOVENOX twice a day; Ear drops twice a day; and FLAGYL 3 times a day; daily; Stopped FLAGYL on 10/21/2022; Stopped FLAGYL on 10/23/2022; Stopped LOVENOX on 10/26/2022 and started on XARELTO twice a day; still currently taking; Had PICC line removed on 11/17/2022 and stopped taking ROCEPHIN; Still has blood clot and getting another MRI soon.
toothache; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) for a Pfizer sponsored program. The reporter is the patient.  A female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) (Batch/Lot number: unknown) as dose 1, single for COVID-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: TOOTHACHE (non-serious), outcome "unknown", described as "toothache".  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
arm area has swollen up 7 inches high and 4 inches wide this is the measurements taken 7 days later. Dark red and hot to it touch. In beginning fever, headache and fatigue.
The pt experienced fever on 1/26/99, followed by rash on 1/27/99 which lasted two days.
Could barely move arm for about first 5 hrs, fever of 100.8, headache, chills and sweating. The second day after shot, I still had chills and sweats and light headed
Diagnosed with COVID-19; This is a spontaneous report from a contactable Pharmacist reported for an unspecified age and gender of patient received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Formulation: Solution for injection), via an unspecified route of administration on 28Jan2021 at single dose for covid-19 immunization. The patient medical history and concomitant medications were not reported. On an unknown date, the patient was  diagnosed with COVID-19. The outcome of the event was unknown.  Follow-up attempts are completed. No further information is expected.
This case was reported by a pharmacist via call center representative and described the occurrence of unwell in a adult patient who received SHINGRIX for prophylaxis. On an unknown date, the patient received SHINGRIX at an unknown dose. On an unknown date, 1 day after receiving SHINGRIX, the patient experienced unwell, generalized aching, chills, fever, influenza-like symptoms and activities of daily living impaired. On an unknown date, the outcome of the unwell, generalized aching, chills, fever, influenza-like symptoms and activities of daily living impaired were recovered/resolved. It was unknown if the reporter considered the unwell, generalized aching, chills, fever, influenza-like symptoms and activities of daily living impaired to be related to SHINGRIX. Additional information was received as follows: The age at vaccination was not reported. The age group was not reported but was selected as adult as per vaccine indication. The patient did receive SHINGRIX some weeks before the reporting date and the patient became ill the next day of the vaccination day with generalized aches, chills, fever and heavy flu-like symptoms. These were severe enough to disabled the patient for a day but only lasted 24 to 36 hours. The reporter asked if those were the common response. It was interesting that they both (the patient's family member who received SHINGRIX refer case US2018GSK151445) reacted exactly the same. The reporter said that any information could offer here would be appreciated. The reporter said that he was recently retired hospital pharmacist so please do not hesitate to offer him provider information. He understood the pharmacology as well as the supply chain issues. This case was one of the 4 link cases, reported by the same reporter.
Symptoms began approximately 12 hours after receiving shot- chills, body aches, loss of appetite. After sleeping from 12am until 11am the next morning, I awoke with fever and extreme exhaustion. I was unable to get out of bed  or stay awake until 5pm, an hour after taking Tylenol.  I also experienced. brain fog for several days after vaccination.
I took the Moderna vaccine on the 15th, my arm has a red PII(28):AdwnHnismDUvdy9+FqxlmmYqxNnr and itchy; took the Moderna vaccine on the 15th, my arm has a red PII(28):AdwnHnismDUvdy9+FqxlmmYqxNnr and itchy; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE ERYTHEMA (I took the Moderna vaccine on the 15th, my arm has a red PII(28):AdwnHnismDUvdy9+FqxlmmYqxNnr and itchy) and VACCINATION SITE PRURITUS (took the Moderna vaccine on the 15th, my arm has a red PII(28):AdwnHnismDUvdy9+FqxlmmYqxNnr and itchy) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) Unknown. On an unknown date, the patient experienced VACCINATION SITE ERYTHEMA (I took the Moderna vaccine on the 15th, my arm has a red PII(28):AdwnHnismDUvdy9+FqxlmmYqxNnr and itchy) and VACCINATION SITE PRURITUS (took the Moderna vaccine on the 15th, my arm has a red PII(28):AdwnHnismDUvdy9+FqxlmmYqxNnr and itchy). At the time of the report, VACCINATION SITE ERYTHEMA (I took the Moderna vaccine on the 15th, my arm has a red PII(28):AdwnHnismDUvdy9+FqxlmmYqxNnr and itchy) and VACCINATION SITE PRURITUS (took the Moderna vaccine on the 15th, my arm has a red PII(28):AdwnHnismDUvdy9+FqxlmmYqxNnr and itchy) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Reporter did not allow further contact
Reason for call:  Patient calls stating that she started to not feel well around 5/4/21, she was tested yesterday for COVID and it came back positive. She had a fever for 1 day, experiences cough, diarrhea, and increased fatigue. She states that it "hasn't been real bad" but she did sound not well. She did get both doses of her COVID vaccine in March.
little tender to touch; a red rash at the injection site; felt warm; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PAIN (little tender to touch), VACCINATION SITE RASH (a red rash at the injection site) and VACCINATION SITE WARMTH (felt warm) in a 70-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 18-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 27-Jan-2021, the patient experienced VACCINATION SITE PAIN (little tender to touch), VACCINATION SITE RASH (a red rash at the injection site) and VACCINATION SITE WARMTH (felt warm). At the time of the report, VACCINATION SITE PAIN (little tender to touch), VACCINATION SITE RASH (a red rash at the injection site) and VACCINATION SITE WARMTH (felt warm) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.
Severe exacerbation of my peripheral neuropathy with severe burning,tingling,numbness,pain; Severe exacerbation of my peripheral neuropathy with severe burning,tingling,numbness,pain; Severe exacerbation of my peripheral neuropathy with severe burning,tingling,numbness,pain; Severe exacerbation of my peripheral neuropathy with severe burning,tingling,numbness,pain; Severe exacerbation of my peripheral neuropathy with severe burning,tingling,numbness,pain; This is a spontaneous report from a contactable consumer or other non-hcp (Patient). A 59-year-old non-pregnant female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, formulation solution for injection; Lot Number: Er8737) via an unspecified route of administration (age at vaccination 59-year) in Left Arm on 03Apr2021 as dose 1, single for COVID-19 immunization. Medical history included Peripheral neuropathy, High cholestrol and Arthritis from an unknown date and unknown if ongoing. Concomitant medications included gabapentin; celecoxib (CELEBREX); rosuvastatin calcium (CRESTOLIP) taken for an unspecified indication, start and stop date were not reported. No known drug allergies were reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccine. Since the vaccination, the patient had not been tested for COVID-19. On 21Apr2021 the patient experienced severe exacerbation of my peripheral neuropathy with severe burning, tingling, numbness, pain. AE resulted in Doctor or other Healthcare professional office/clinic visit. No treatment was received for the adverse events. The clinical outcome of the events was recovered with sequel (recovered with lasting effects) on an unspecified date.   Follow-Up (15Jul2021): Follow-up attempts are completed. No further information is expected.
I experienced symptoms of congestion, cough, fever, rash (from cough medicine). I was advised by a healthcare provider to take neonasal rinse, zyrtec, cough syrup, flonase generic. I  was prescribed loniculast and benzontate for cough. I am still congested and experiencing headaches, milder cough, but the rash, and fever are resolved.
The patient received Td vaccination in her right hip area on 12/06/07.  Approximately 24 hours later, she developed a local site reaction consisting of pain and swelling at the injection site.  She also complained of swelling in her right upper thigh/lower abdominal area.  The doctor prescribed the antibiotic, cephalosporin.  Additional information received 12/21/07: The patient's adverse reactions have completely resolved.
Intermittent positional vertigo/dizziness; lasts for less than 30 seconds; occurs on standing; sitting
Lump at injection site, very hot & red color to skin around injection site. Grew bigger for first 2 days. Patient treated using ice and massage of immediate area.
Fever "104", nausea and vomiting. Treatment - supportive/antipyretics. Duration: 12 hours.
received an expired dose; This spontaneous case was reported by a consumer and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (received an expired dose) in a 76-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 016s21-29) for COVID-19 vaccination.     Previously administered products included for Product used for unknown indication: Pfizer, Pfizer and Pfizer. Past adverse reactions to the above products included No adverse event with Pfizer, Pfizer and Pfizer.    On 06-Apr-2022, the patient received fourth dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 06-Apr-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (received an expired dose). At the time of the report, EXPIRED PRODUCT ADMINISTERED (received an expired dose) outcome was unknown.            No concomitant medication information was provided.  It was reported that the patient had previously received 3 Pfizer vaccines and then received the second Moderna booster dose on 06-Apr-2022.  Further it was reported that the patient wanted to know how this would affect future vaccination and what was the efficacy of an expired vaccine.  No treatment information was provided.   Most recent FOLLOW-UP information incorporated above includes: On 12-Apr-2022: Follow up contains significant information: patient details (date of birth) updated, historical vaccine added.
Parent reports approximately 2 hours after the vaccine was given that patient reported he had a headache. Tylenol was given and headache subsided. Approximately 21/2 hours later patient described his rt arm as "itchey". Parent denies any redness or warmth at the injection site. After 1/2 hour the itching subsided. The following morning on 11/21/19  the patient woke up with a slightly swollen rt. upper eyelid. Parent denies any
After flu shot on 10/20/14: done by pharmacy. Vaccine: FLUZONE MFG: Sanofi. Dose (ml): 0.50 ml. 10/20: That was done at about 11 am. After three hours I feel strange matter in both throats. Then, after 2 hours my eyes became red inside and with white spots. Those situations were over during the night. Next day I had light headache. This was for 3 days. Also for 3 days I did not go to toilet (constipation) and after I eat meals my stomach was not normal. Sensation of filling. Now my throat was full of secretion. I had some cough. 10/24: I took magnesium sulfate: 2 teaspoons in 8 ounces of water for the constipation. After 8 hours the defecation came. 10/26: For 3 days I developed: coughing, runny nose, sneezing, sore throat and general 'achy' feeling. This reaction is reported by myself to VAERS. It is the first time this happen to me.
45 minutes after shot was given, pt c/o tongue numbness, SOB-wheezing, dizziness. 2 Benadryl 25mg given at onset. 1 dose Adult Epi-pen injected. No loss of consciousness. Seen by her doctor.
Localized: significant bleeding upon administration. Immediate swelling to a knot and bruising. Ping pong ball size. Bleeding stopped externally upon bandaid application. Pt then informed pharmacist upon monitoring that she checked her blood sugar which was dropping into the low 80s. Applied ice compress to vaccine administration site. Monitored pt ~30 minutes. Swelling decreased significantly. no patient complaints- just that she was embarrassed. Gave pt a bottle of orange juice from the store and had her continue to monitor blood glucose levels. Upon releasing the patient, she had a blood glucose reading of 110 (~30 minutes observation).